Summary
New prescriptions for ADHD stimulant medications among adults more than doubled since the COVID-19 pandemic began, with the sharpest rises among those aged 18-44, particularly young adults and women, according to a CMAJ study from Ontario researchers.[1][4] Rates increased 7.3 times faster post-pandemic, reaching 0.44 new dispensations per 1,000 adults by mid-2024, amid similar trends in the US, UK, Australia, and Finland.[2][4][6] Factors include greater awareness, virtual care expansion, and co-occurring anxiety/depression, though psychiatrist prescriptions declined while nurse practitioners stepped up.[1][4]
Key Takeaways
- New adult ADHD stimulant prescriptions doubled since COVID-19, surging 7.3 times faster post-pandemic.[1][4]
- Youngest adults (18-24) and women drove the steepest increases, flipping pre-pandemic gender parity.[3][4]
- Virtual care and awareness boosted access, but psychiatrist prescriptions fell from 26% to 18%.[4]
- Similar trends hit US (14-32% rise), UK (18% annual), and beyond, with sustained demand.[2][6]
- 25% of new users had anxiety/depression diagnoses, hinting at off-label or comorbid use.[4]
Balanced Perspective
Data from Ontario shows new adult stimulant prescriptions doubled post-pandemic, primarily for ADHD, with monthly increases 7.3 times pre-pandemic rates, concentrated in 18-44 age groups.[1][4] US studies confirm 14-32% rises in ADHD meds versus stable or declining other psychotropics, driven by demographics like young adults and women.[2][7] While improved diagnostics and telehealth explain part of the trend, researchers note incomplete understanding of drivers like screen time or distress, with sustained growth through 2024.[1][4]
Optimistic View
This surge signals a breakthrough in mental health destigmatization, finally recognizing ADHD in adults long overlooked, especially younger women who faced diagnostic barriers pre-pandemic.[3][4] Expanded virtual care democratizes access, enabling timely treatment that boosts productivity, focus, and quality of life for millions worldwide.[1][2] With global trends accelerating positively post-2020 dips, we're on track for better societal support, turning potential into performance as awareness fuels proactive care.[5]
Critical View
The explosion in prescriptions risks overdiagnosis and inappropriate stimulant use, especially off-label for anxiety or depression in untreated young adults amid pandemic stress.[1][4] Declining psychiatrist involvement and rising nurse practitioner scripts, plus virtual care's lax oversight, heighten misuse potential in a high-demand environment with limited long-term safety data.[2][4] Global patterns suggest societal pressures like screens and distress inflate cases, potentially fueling dependency, diversion, and overlooked root causes like lifestyle factors.[1][5]
Source
Originally reported by pharmacy.utoronto.ca